Celldex Therapeutics, Inc. (CLDX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Celldex Therapeutics, Inc. (CLDX)

Company Performance

Current Price

as of Oct 11, 2024

$31.32

P/E Ratio

N/A

Market Cap

$1.97B

Description

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Metrics

Overview

HQHampton, NJ
SectorHealth Technology
IndustryBiotechnology
TickerCLDX
Price$31.32+5.53%

Trading Information

Market Cap$1.97B
Float96.86%
Average Daily Volume (1m)1,570,267
Average Daily Volume (3m)986,877
EPS-$2.74

Company

Revenue$8.30M
Rev Growth (1yr)832.09%
Net Income-$35.84M
Gross Margin68.09%
EBITDA Margin-1,822.26%
EBITDA-$45.52M

EV$1.65B
EV/Revenue198.53
P/EN/A
P/S236.02
P/B2.42

Documents

Factset Street Account

Celldex Therapeutics upgraded to equal weight from underweight at Wells Fargo Securities ($25.78, 0.00) (2023-11-10T11:35:22Z)

Celldex Therapeutics secondary priced at $27/share through Jefferies, Leerink, we're told ($29.02, 0.00) (2023-11-08T01:52:49Z)

Celldex Therapeutics reports positive data from Phase 1B study of barzolvolimab in prurigo nodularis ($25.98, 0.00) (2023-11-05T20:05:37Z)

Celldex Therapeutics announces topline results from barzolvolimab Phase 2 study in chronic spontaneous urticaria ($25.98, 0.00) (2023-11-06T11:32:38Z)

Earnings Calls

Earnings Report 2021Q4

Earnings Report (2022-02-28)